CapsoVision (CV) Q2 2026 earnings review
Volume Recovers, But Cash Burn and Slipping Timelines Force a $100M ATM
CapsoVision demonstrated an encouraging top-line rebound in Q2, with revenue growing 10% to $3.6M driven by a 13% acceleration in capsule volume. However, the underlying financials paint a deteriorating picture. Gross margins compressed to 51% due to tariff and pricing pressures, and operating expenses surged to $9.5M. This toxic combination drove cash down from $17.9M last quarter to just $9.1M. Management's quiet initiation of a massive $100M At-The-Market (ATM) offering signals that aggressive shareholder dilution is imminent. Furthermore, key pipeline milestones have slipped slightly compared to prior guidance.
🐂 Bull Case
After a weak Q1 where capsule shipments fell 3%, Q2 saw a reversal with volume jumping 13%. This validates management's prior claim that Q1 weakness was merely a timing issue, not structural demand destruction.
AI Highlights launched commercially in the EU, expanding the platform's value proposition. A US launch is teed up for late Q3, pending FDA clearance, which could drive a re-acceleration in hardware adoption.
🐻 Bear Case
With only $9.1M in cash remaining and a quarterly OpEx run-rate of $9.5M, the company has its back against the wall. The newly filed $100M ATM facility will likely be heavily utilized, severely diluting current equity holders.
Management quietly pushed the CapsoCam Colon Gen 2 510(k) submission from Q3 (guided in prior quarters) to Q4. In early-stage medtech, slipping timelines translate directly to extended cash burn.
⚖️ Verdict: 🔴
Bearish. Top-line recovery is overshadowed by a deteriorating balance sheet, compressing margins, and a pipeline that is losing schedule integrity. The $100M ATM is the primary takeaway for investors this quarter.
Key Themes
Liquidity Crisis and Impending Dilution
The balance sheet is flashing red. Cash dropped precipitously from $17.9M at the end of Q1 to just $9.1M this quarter. With an operating cash burn currently outpacing revenue by almost 3-to-1, the company filed a $100M ATM offering with Cantor. Given the company's current valuation, tapping this ATM to fund the aggressive $9.5M/quarter OpEx run-rate will result in massive shareholder dilution.
Gross Margin Compression and Pricing Pressure
Gross margin decelerated to 51% from 55% in the prior year. This 400 bps compression was driven by two factors: a 3% decline in Average Selling Price (ASP) due to competitive pressures, and increased customs/tariffs. In previous quarters, management touted a shift to higher-priced geographic regions; this quarter's ASP drop contradicts that narrative and reveals weakening pricing power in the core business.
Pipeline Milestones Quietly Slipping
Despite management's claim that the pipeline continues to advance, key dates are slipping. The CapsoCam Colon Gen 2 510(k) submission, explicitly promised for Q3 2026 in the last earnings cycle, is now guided for Q4. Additionally, AI Highlights clearance was previously expected 'around mid-year' and is now pushed to 'the end of the third quarter.' These micro-delays add up, prolonging the timeline to high-margin commercial revenue and exacerbating cash burn.
Core CapsoCam Plus Volume Recovery
The bright spot in Q2 was an accelerating core business. Capsule volumes grew 13% YoY, completely reversing the 3% contraction seen in Q1. This proves that the Q1 dip was indeed tied to order timing rather than a fundamental shift away from the platform by large hospital systems.
AI Highlights Reaches the Market
The company formally launched AI Highlights commercially in the European Union. By acting as an AI-assisted workflow tool that reduces the time physicians spend reviewing small bowel studies, this software directly addresses the biggest friction point in capsule endoscopy. If successful in the EU, it sets a strong precedent for the highly anticipated US launch later this year.
Other KPIs
R&D costs are accelerating aggressively, jumping 56% YoY from $3.39M in 25Q2. This massive step-up is driven by the pivotal colon study, clinical trials for pancreatic cancer, and non-recurring engineering fees to Canon for the new CMOS sensor. This is the primary driver of the company's precarious cash situation.
Combined SG&A expenses grew 35% YoY from $3.07M. The increase in G&A specifically ($2.2M vs $1.2M YoY) was attributed to public company operating expenses and higher stock-based compensation, showing that corporate overhead is expanding right alongside pipeline investment.
Guidance
Decelerating/Delayed. In Q1, management guided for clearance 'around mid-year'. This has officially been pushed to the end of Q3. Consequently, the associated U.S. commercial revenue boost will now likely be deferred entirely to Q4 or early 2027.
Decelerating/Delayed. The submission timeline has slipped by a full quarter compared to the prior firm guidance of Q3 2026. This calls into question the previously stated target of achieving commercial availability by the second half of 2027.
Key Questions
ATM Utilization Strategy
With only $9.1 million in cash and a newly filed $100 million ATM, what is the anticipated cadence of equity sales? Are there minimum price thresholds the board has set, or will shares be sold at the market to immediately fund the $9M+ quarterly OpEx run rate?
Gross Margin and ASP Degradation
Gross margin fell 400 basis points YoY, and ASP declined by 3%. Given that tariffs are a known headwind, what specific competitive dynamics are forcing you to lower prices, and do you expect gross margins to dip below 50% in the second half of the year?
Pipeline Delays
The CapsoCam Colon 510(k) submission has been pushed from Q3 to Q4. Was this delay related to clinical enrollment speed, trial data quality, or bandwidth issues with your regulatory team?